Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

BACKGROUND: The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antibody-dependent cellular cytotoxicity (ADCC) induced by type I/II anti-CD20 antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Albertsson-Lindblad, Alexandra, Freiburghaus, Catja, Jerkeman, Mats, Ek, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685275/
https://www.ncbi.nlm.nih.gov/pubmed/31406628
http://dx.doi.org/10.1186/s40164-019-0141-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685275/
https://www.ncbi.nlm.nih.gov/pubmed/31406628
http://dx.doi.org/10.1186/s40164-019-0141-1

Ejemplares similares